YDO1 Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Madrigal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$298.70 |
| 52 Week High | US$336.00 |
| 52 Week Low | US$155.10 |
| Beta | -0.47 |
| 11 Month Change | 60.08% |
| 3 Month Change | 33.41% |
| 1 Year Change | 73.46% |
| 33 Year Change | 295.63% |
| 5 Year Change | 200.08% |
| Change since IPO | 114,344.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| YDO1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.6% | 0.8% | -0.4% |
| 1Y | 73.5% | -16.7% | 7.1% |
Return vs Industry: YDO1 exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: YDO1 exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| YDO1 volatility | |
|---|---|
| YDO1 Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YDO1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: YDO1's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 376 | Bill Sibold | www.madrigalpharma.com |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. Fundamentals Summary
| YDO1 fundamental statistics | |
|---|---|
| Market cap | €6.56b |
| Earnings (TTM) | -€491.75m |
| Revenue (TTM) | €72.83m |
90.0x
P/S Ratio-13.3x
P/E RatioIs YDO1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YDO1 income statement (TTM) | |
|---|---|
| Revenue | US$76.81m |
| Cost of Revenue | US$2.79m |
| Gross Profit | US$74.03m |
| Other Expenses | US$592.70m |
| Earnings | -US$518.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -23.78 |
| Gross Margin | 96.37% |
| Net Profit Margin | -675.24% |
| Debt/Equity Ratio | 15.1% |
How did YDO1 perform over the long term?
See historical performance and comparison